A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Inclusion Criteria:

• Documented multiple myeloma satisfying the calcium elevation, renal insufficiency,anemia, and bone abnormalities (CRAB) diagnostic criteria, monoclonal plasma cells inthe bone marrow greater than or equal to (>=) 10 percent (%) or presence of a biopsyproven plasmacytomas, and measurable secretory disease, as assessed by the centrallaboratory, and defined in protocol
• Newly diagnosed and not considered candidate for high-dose chemotherapy with stem celltransplantation (SCT) due to: being age >= 65 years, or in participants less than (<) 65 years: presence of important comorbid conditions likely to have a negative impacton tolerability of high dose chemotherapy with stem cell transplantation
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
• Meet the clinical laboratory criteria as specified in the protocol
• A woman of childbearing potential must have a negative serum or urine pregnancy testsat screening within 14 days prior to randomization

Exclusion Criteria:

• Primary amyloidosis, monoclonal gammopathy of undetermined significance, or smolderingmultiple myeloma
• Waldenstrom's disease, or other conditions in which Immunoglobulin M (IgM) M-proteinis present in the absence of a clonal plasma cell infiltration with lytic bone lesions
• Prior or current systemic therapy or SCT for multiple myeloma, with the exception ofan emergency use of a short course (equivalent of dexamethasone 40 milligram per day (mg/day) for 4 days) of corticosteroids before treatment
• Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by thenational cancer institute common terminology criteria for adverse events (NCI-CTCAE),Version 4.03
• History of malignancy (other than multiple myeloma) within 3 years before the date ofrandomization (exceptions are squamous and basal cell carcinomas of the skin andcarcinoma in situ of the cervix, or malignancy that in the opinion of theinvestigator, with concurrence with the sponsor's medical monitor, is considered curedwith minimal risk of recurrence within 3 years)
• Radiation therapy within 14 days of randomization
• Seropositive for hepatitis B (defined by a positive test for hepatitis B surfaceantigen [HBsAg]). Participants with resolved infection (that is, participants who areHBsAg negative but positive for antibodies to hepatitis B core antigen [Anti-HBc]and/or antibodies to hepatitis B surface antigen [Anti-HBs]) must be screened usingreal-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV)deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.EXCEPTION: Participants with serologic findings suggestive of HBV vaccination (Anti-HBs positivity as the only serologic marker) AND a known history of prior HBVvaccination, do not need to be tested for HBV DNA by PCR